By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Vermillion today reported $413,000 in revenues for the third quarter, led by licensing revenues.
In the year-ago period when the Austin, Texas-based molecular diagnostics company was in Chapter 11, it posted no revenues.
Registering provides access to this and other free content.
Already have an account?Login Now.
A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.
UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.
Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.
In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.